Biotest

Biotest, a Pharmaceutical Preparation Manufacturing company headquartered in Germany, reported its latest carbon emissions for 2025 as approximately 130,372,600 kg CO2e. This total includes Scope 1 emissions of 17,480,600 kg CO2e, market-based Scope 2 emissions of 26,000,500 kg CO2e, and Scope 3 emissions of 86,891,500 kg CO2e. Key categories within Scope 3 include purchased goods and services (60,054,400 kg CO2e), capital goods (6,485,300 kg CO2e), fuel and energy related activities (6,312,600 kg CO2e), waste generated in operations (5,892,300 kg CO2e), and upstream transportation and distribution (4,062,500 kg CO2e).

For 2024, Biotest reported total emissions of approximately 134,539,400 kg CO2e, with Scope 1 emissions at 17,035,400 kg CO2e, market-based Scope 2 emissions at 25,289,000 kg CO2e, and Scope 3 emissions at 92,215,000 kg CO2e.

In 2023, the company's total emissions were approximately 139,158,000 kg CO2e, comprising Scope 1 emissions of 15,210,000 kg CO2e, market-based Scope 2 emissions of 21,905,000 kg CO2e, and Scope 3 emissions of 102,043,000 kg CO2e.

Looking further back, in 2022, Biotest reported Scope 1 emissions of 18,185,600 kg CO2e and Scope 2 emissions of 930,500 kg CO2e. In 2021, their Scope 1 emissions were 1,136,500 kg CO2e (including 1,119,400 kg CO2e from fugitive emissions and 17,100 kg CO2e from mobile combustion) and Scope 2 emissions were 711,000 kg CO2e from purchased electricity, totalling approximately 2,054,400 kg CO2e for Scope 1 and 2.

Biotest is a current subsidiary of Biotest Aktiengesellschaft, and its SBTi targets are cascaded from its ultimate parent through the corporate family relationship with Grifols, S.A. Biotest has disclosed its climate commitments through a sustainability statement, however, specific reduction targets or climate pledges were not provided in the available data.